64 higher-income economies are pooling financial and scientific resources, to insure themselves against the failure of any individual vaccine candidate and secure successful vaccines in a cost-effective, targeted way.
The 64 members of the Facility will be joined by 92 low- and middle-income economies eligible for support for the procurement of vaccines through the Gavi COVAX Advance Market Commitment (AMC), a financing instrument aimed at supporting the procurement of vaccines for these countries. This means that 156 economies, representing roughly 64% of the global population in total, are now either committed to or eligible for the COVAX Facility, with more to follow.
“COVAX is now in business: governments from every continent have chosen to work together, not only to secure vaccines for their own populations but also to help ensure that vaccines are available to the most vulnerable everywhere,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance, which is coordinating the COVAX Facility. “With the commitments, we’re announcing today for the COVAX Facility, as well as the historic partnership we are forging with industry, we now stand a far better chance of ending the acute phase of this pandemic once safe, effective vaccines become available.”
COVAX and the idea of equal access to a COVID-19 vaccine, regardless of ability to pay, is not just a moral imperative, it is the only practical solution to this pandemic. Protecting everyone is the only way we can return our world – our trade, tourism, travel, business – to normal,” said the Honourable Dr Edwin G. Dikoloti, Minister of Health and Wellness for Botswana. “We urge those countries who have not yet signed up to do so. Let us work together to protect each other.”
“Immunisation saves lives. Investing in immunisation infrastructure helps strengthen health systems. We have seen this time and again through our work with Gavi and Alliance partners,” said Dr Lia Tadesse, Minister of Health for Ethiopia. “By being a part of the COVAX Facility and the AMC we can continue this work and protect our citizens – and the world – against the impact of COVID-19.”
“With COVAX, the world is joining forces and proving that together, we are stronger – and together, we can defeat this pandemic,” said Ekaterine Tikaradze, Minister of Health for Georgia. “Georgia will be joining the COVAX Facility to give our citizens the best chance at having access to safe vaccines. By doing this, we also make sure health care workers and other high risk persons all over the world have access to these life-saving tools, helping to bring the pandemic under control – and we can all recover and rebuild.”
“Joining the COVAX Facility was not a difficult decision – not only will this give Kuwaiti citizens access to COVID-19 vaccines as they become available, it will also mean our friends and partners outside our borders also get access,” said His Excellency Sheikh Dr Basel Humoud Al-Sabah, Minister of Health of the State of Kuwait. “We need a global solution to this global pandemic: we believe COVAX is that solution.”
The COVAX Facility is part of COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, which is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, and the World Health Organization (WHO) – working in partnership with developed and developing country vaccine manufacturers, UNICEF, the World Bank, Civil Society Organisations and others.
The allocation of vaccines, once licensed and approved, will be guided by an Allocation Framework released today by WHO following the principle of fair and equitable access, ensuring no participating economy will be left behind. Policies determining the prioritization of vaccine rollout within economies will be guided by recommendations from the WHO Strategic Advisory Group of Experts on Immunization (SAGE), which has recently released a Values Framework laying the groundwork for subsequent guidance on target populations and policies on vaccine use.
“COVID-19 is an unprecedented global crisis that demands an unprecedented global response,” said WHO Director-General, Dr Tedros Adhanom Ghebreyesus. “Vaccine nationalism will only perpetuate the disease and prolong the global recovery.
Working together through the COVAX Facility is not charity, it’s in every country’s own best interests to control the pandemic and accelerate the global economic recovery.”
The commitment of fully self-financing economies will now unlock vital funding and the security of demand needed to scale up manufacturing and secure the doses needed for the Facility. CEPI is leading COVAX vaccine research and development work, which aims to develop at least three safe and effective vaccines which can be made available to economies participating in the COVAX Facility. Nine candidate vaccines are currently being supported by CEPI; eight of which are currently in clinical trials.
“This is a landmark moment in the history of public health with the international community coming together to tackle this pandemic. The global spread of COVID-19 means that it is only through equitable and simultaneous access to new lifesaving COVID-19 vaccines that we can hope to end this pandemic”, said Dr Richard Hatchett, CEO of CEPI. “Countries coming together in this way shows a unity of purpose and resolve to end the acute phase of this pandemic, and we must now work closely with vaccine manufacturers—who play an integral part in the global response—to put in place the agreements needed to fulfil COVAX’s core aim: to have two billion vaccine doses available by the end of 2021. Today, we have taken a great leap towards that goal, for the benefit of all.”